Quince Therapeutics Inc banner

Quince Therapeutics Inc
NASDAQ:QNCX

Watchlist Manager
Quince Therapeutics Inc Logo
Quince Therapeutics Inc
NASDAQ:QNCX
Watchlist
Price: 1.37 USD 2.24%
Market Cap: $22.3m

During the last 3 months Quince Therapeutics Inc insiders have not bought any shares, and have not sold any shares. The stock price has dropped by 96% over this period (open performance analysis).

The last transaction was made on Dec 26, 2025 by Benatti Luca , who sold 173.5k USD worth of QNCX shares.

Last Transactions:
Benatti Luca
$-17.4k
Thye Dirk
$+53.9k
Thye Dirk
$+53.5k
Hannah Brendan
$+1.4k
Hannah Brendan
$+1.5k
Ryan Charles S.
$+31.5k
Hannah Brendan
$+1.2k
Lamond David
$+23.5k
Lamond David
$+22.6k
Lamond David
$+300
Lamond David
$+19.3k
Lamond David
$+19.5k
Lamond David
$+19.3k
Lamond David
$+13.5k
Lamond David
$+12.9k
Lamond David
$+14.1k
Lamond David
$+54.2k
Lamond David
$+53.7k
Lamond David
$+31.9k
Lamond David
$+151.4k
Lamond David
$+142.4k
Thye Dirk
$+110.9k
Thye Dirk
$+99.2k
Mcloughlin Margaret
$+9.8k
Hannah Brendan
$+87.5k
Monohon Ted
$-1.8k
Mcdowell Caryn Gordon
$-30.9k
Dominy Stephen S.
$+11k
Mcloughlin Margaret
$-88.9k
Lowe Christopher P.
$-488.9k
Lowe Christopher P.
$-863k
Mcloughlin Margaret
$-288.9k
View All Transactions

During the last 3 months Quince Therapeutics Inc insiders have not bought any shares, and have not sold any shares. The stock price has dropped by 96% over this period (open performance analysis).

The last transaction was made on Dec 26, 2025 by Benatti Luca , who sold 173.5k USD worth of QNCX shares.

Sold
0-3
months
0 USD
0
3-6
months
17.4k USD
1
6-9
months
0 USD
0
9-12
months
0 USD
0
Bought
0-3
months
No Insider Transactions
0
0 USD
3-6
months
0
0 USD
6-9
months
No Insider Transactions
0
0 USD
9-12
months
No Insider Transactions
0
0 USD

Quince Therapeutics Inc
Insider Trading Chart

Quince Therapeutics Inc
Insiders Performance

1 Week Later 1 Month Later 3 Months Later 6 Months Later 1 Year Later
Average Return
Median Return
Win Rate

Quince Therapeutics Inc
Last Insider Transactions

Global
Insiders Monitor

Quince Therapeutics Inc
Glance View

Market Cap
22.3m USD
Industry
Biotechnology

Cortexyme, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics. The company is headquartered in South San Francisco, California and currently employs 55 full-time employees. The company went IPO on 2019-05-09. The firm is focused on advancing precision therapeutics targeting debilitating and rare diseases. The firm has discovered a bone-targeting drug platform capable of delivering small molecules, peptides, or large molecules directly to the site of broad bone fractures and disease designed to promote more healing with fewer off-target safety concerns. The Company’s lead compound, NOV004, is an anabolic peptide engineered to target and concentrate at the bone fracture site. Its discovery pipeline is focused on expanding across multiple skeletal therapeutic indications, including osteogenesis imperfecta, fractures, spinal fusion, and other severe diseases of bone such as cancer or infection. The firm's pipeline also includes legacy neuroscience and antiviral programs available for out-licensing, which include COR588, COR388, COR852 and COR803.

QNCX Intrinsic Value
Not Available

What is Insider Trading?

Insider trading refers to the buying or selling of a company’s stock by individuals with access to non-public, material information about the company.

While legal insider trading occurs when insiders follow disclosure rules, illegal insider trading involves trading based on confidential information and is prohibited by law.

Why is Insider Trading Important?

It isn't a coincidence that corporate executives seem to always buy at the right times. After all, they have access to every bit of company information you could ever want.

However, the fact that company executives have unique insights doesn't mean that individual investors are always left in the dark. Insider trading data is out there for all who want to use it.

Peter Lynch

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett